MDT

87.95

+0.96%↑

117.5

+2.09%↑

VEEV

158.5

+4.65%↑

HQY

79.86

+2.23%↑

TLRY

6.73

+2.28%↑

MDT

87.95

+0.96%↑

117.5

+2.09%↑

VEEV

158.5

+4.65%↑

HQY

79.86

+2.23%↑

TLRY

6.73

+2.28%↑

MDT

87.95

+0.96%↑

117.5

+2.09%↑

VEEV

158.5

+4.65%↑

HQY

79.86

+2.23%↑

TLRY

6.73

+2.28%↑

MDT

87.95

+0.96%↑

117.5

+2.09%↑

VEEV

158.5

+4.65%↑

HQY

79.86

+2.23%↑

TLRY

6.73

+2.28%↑

MDT

87.95

+0.96%↑

117.5

+2.09%↑

VEEV

158.5

+4.65%↑

HQY

79.86

+2.23%↑

TLRY

6.73

+2.28%↑

Home・Aandelen Lijst・Celldex Therapeutics Inc

Celldex Therapeutics Inc

Open

SectorGezondheidszorg

32.38 0.59

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

32.05

Max

32.73

Belangrijke statistieken
By Trading Economics
Inkomsten	-14M -81M
Verkoop	75K 75K
EPS	-1.22
Winstmarge	-108,422.667
Werknemers	198
EBITDA	-7.8M -81M

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+69.04% upside

Dividenden
By Dow Jones
Volgende Winsten	6 mei 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	472M 2.1B
Vorige openingsprijs	31.79
Vorige sluitingsprijs	32.38

Nieuwssentiment

By Acuity

100%

330 / 348 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Weak Bullish Evidence

18.91 / 20.63 Steun & Weerstand

Celldex Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

12 apr 2026, 23:44 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Nikkei Likely to Fall After U.S.-Iran Peace Talks Break Down -- Market Talk

12 apr 2026, 23:38 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Oil Climbs as U.S.-Iran Peace Talks Fail, U.S. Navy Starts Blockade of Strait of Hormuz -- Market Talk

12 apr 2026, 23:38 UTC

Marktinformatie

Australia's Upstream Energy Companies Poised for Consensus Earnings Upgrades -- Market Talk

12 apr 2026, 23:36 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Gold Falls as Dollar Strengthens After U.S.-Iran Peace Talks Collapse -- Market Talk

12 apr 2026, 23:31 UTC

Marktinformatie

A2 Milk's Supply Issues Likely Temporary -- Market Talk

12 apr 2026, 23:09 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Australian Dollar Hammered by Blockade of Iran Ports -- Market Talk

12 apr 2026, 23:06 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

12 apr 2026, 23:06 UTC

Marktinformatie

Australian Dollar Ripe for a Downward Correction -- Market Talk

12 apr 2026, 22:56 UTC

Belangrijke Nieuwsgebeurtenissen

Spot Gold Falls 1.9% to $4,658.65 per Ounce

12 apr 2026, 22:54 UTC

Belangrijke Nieuwsgebeurtenissen

Front-Month Brent Crude Oil Futures Rise 7.6% to $102.42 per Barrel

12 apr 2026, 22:53 UTC

Belangrijke Nieuwsgebeurtenissen

Front-Month WTI Crude Oil Futures Rise 8.3% to $104.56 per Barrel, ICE Data Show

12 apr 2026, 22:51 UTC

Belangrijke Nieuwsgebeurtenissen

Front-Month Crude Oil Futures Climb After U.S.-Iran Peace Talks Break Down

12 apr 2026, 22:50 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

US Dollar Climbs Amid Broad Risk Off Mood In FX Market -- Market Talk

12 apr 2026, 22:37 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Australian Dollar Under Fire as Middle East Tensions Ratchet Up Again -- Market Talk

11 apr 2026, 08:20 UTC

Marktinformatie

Energy & Utilities Roundup: Market Talk

11 apr 2026, 08:20 UTC

Marktinformatie

Health Care Roundup: Market Talk

11 apr 2026, 08:20 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Basic Materials Roundup: Market Talk

11 apr 2026, 00:00 UTC

Winsten

Acquisities, Fusies, Overnames

Big Yachts, Big Bucks -- Barrons.com

10 apr 2026, 21:55 UTC

Acquisities, Fusies, Overnames

Paramount Warrants Are an Underappreciated Aspect of Warner Bros. Deal -- Barrons.com

10 apr 2026, 21:01 UTC

Winsten

Cango Inc.: Files Annual Report on Form 20-F With SEC

10 apr 2026, 20:50 UTC

Marktinformatie

Energy & Utilities Roundup: Market Talk

10 apr 2026, 20:50 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Basic Materials Roundup: Market Talk

10 apr 2026, 20:50 UTC

Marktinformatie

Health Care Roundup: Market Talk

10 apr 2026, 20:31 UTC

Marktinformatie

Convenience Store Traffic Slows as Gas Prices Rise -- Market Talk

10 apr 2026, 20:10 UTC

Acquisities, Fusies, Overnames

This Women's Health Company Is Drawing Takeover Interest. The Stock Is Soaring. -- Barrons.com

10 apr 2026, 19:15 UTC

Marktinformatie

Global Energy Roundup: Market Talk

10 apr 2026, 19:15 UTC

Marktinformatie

Oil Futures Settle Lower With Focus on U.S.-Iran Talks -- Market Talk

10 apr 2026, 19:08 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

10 apr 2026, 19:08 UTC

Marktinformatie

U.S. Natural Gas Futures End Week Lower -- Market Talk

10 apr 2026, 18:38 UTC

Marktinformatie

Canada's Job Market Showing Soft Demand, Structural Decline in Supply -- Market Talk

Peer Vergelijking

Prijswijziging

Celldex Therapeutics Inc Prognose

Koersdoel

By TipRanks

69.04% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 54.5 USD 69.04%

Hoogste 90 USD

Laagste 24 USD

Gebaseerd op 11 Wall Street-analisten die 12-maands prijsdoelen bieden voor Celldex Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

11 ratings

Buy

Hold

Sell

Gebaseerd op 11 analisten die aandelenratings hebben gegeven aan Celldex Therapeutics Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

18.91 / 20.63Steun & Weerstand

Recent bullish events outweigh bearish events.

All events are bearish.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.